ritobegron + propranolol

**Ritobegron + propranolol** is a combination of two small molecule drugs: **ritobegron** (a highly selective β3-adrenergic receptor agonist, developed for overactive bladder and related urological indications) and **propranolol** (a non-selective β-adrenergic receptor antagonist commonly used for cardiovascular diseases and other indications). Ritobegron acts by activating β3-adrenergic receptors, resulting in detrusor muscle relaxation and improving bladder storage capacity. Propranolol blocks β1-, β2-, and, with low affinity, β3-adrenergic receptors, thereby having opposing effects on adrenergic signaling. The combination is investigated for pharmacological interactions, mainly in drug metabolism and receptor selectivity studies; it is not established as a marketed therapeutic product but appears in clinical trials as a co-medication for evaluating metabolic or receptor effects[1][3][5]. Ritobegron development for overactive bladder reached phase III but was discontinued[1][4]. Propranolol is an established and marketed drug.

Other names

ritobegron + propranolol